14 24 7 16 27 37 9 Both CT and MR were perfomed in 18 patients and identified organic lesions (OTPP) in 4 patients (34 1F 1 hamartoma, 2 germinomas and 1 post-traumatic sequelae). In 10 cases only MR was performed and 1 girl with and expanding hypothalamic lesion (hamartoma) was detected.We conclude that despite improved techniques the incidence of organic lesions in females with TPP has not changed. We suggest MR should be the imaging technique of choice in the diagnosis of TPP because it gives a better image without radiation exposure. With the aim of determining maternal and newborn levels of catecholamines during birth, we measured simultaneously samples from mother's peripheral vein and umbilical cord in 20 cases. Fifteen births resulted from ceasarean.sections and 5 had vaginal delivery. Maternal age ranged from 20 to 42 years and gestational age varied from 35 weeks. Maternal and newborn outcomes were uneventful.Mean levels of catecholamines (and SD)are shown in the 
ETIOUXIC DIAGNOSIS OF TRUE PRECOCIOUS PUBERTY (TPP) BY CONPUTED TOWOGRAPHY (CT) AND MAGNETIC RESONANCE (NR)
The uterotrophic placental factor (UTPF) has been described in human placental extracts and in placental extracts of other species such us mouses, dogs. pigs. and cows. In this work we compare physicochemical characteristics (PAGE.SDS and blotting) and plasmatic levels (inmunoassays) of UTPF in human (hUTPF) and bovine (bUTPF). The purification methodology used has been described by us. By PAGE.SDS. bUTPF presented a molecular weight of 230 Kd and hUTPF 270 the antibody against hUTPF recognized the 230 Kd bovine line (by blotting). The plasmatic levels of bUTPF were measured by an EIA, showing a peak at about the third week of gestation, similar to the previously described for hUTPF (9 -18 days post-transference). These results suggest, if they are confirmed in other species. that UTPF could be an early universal marker of mammals gestation.
This 0.001).Among girls, only at 14 years of age there are differences between M+PSS (28.7%) versus P (15.7) (p<0.04). Obesity prevalence among parents of obese children: a single parent 22.2%. both parents 4.7%; control group 10.3% and 1.1% respectiely (p<0.001). 27% Obesity among brothers and sisters of obese children and 11.9% in controls (p < 0.001). No difference was found between obese and non obese children concerning divorced parent, a single child, parents schooling.School marks.physica1 activity, daily calorie intake were similar for both groups. The prevalence of obesity in our sample: 21%. Clustered by age and sex.girls are more obese at age 14.It was more prevalent among males attending P. Among girls there is only a difference at age 14,being more prevalent in M+PSS schools. Fami-ly background was the only conditioning factor.This study allows us to identify the groups at risk among school children and start preventive measures. We studied 12 children (11 F.1M) with idiopathic short stature. aged 11.5+0.35 years (9.6-12.7 yr), height age 9.9+0.21yr(9.0-11.2yr),bone age 11.17+0.24yr(10.0-13.0yr) and height standard deviation for age -1.8 +_ 0.33 SD. All were pubertal at start (3 Tanner 11. 9 Tanner 111) and had a short final height prediction according to the Bayley Pinneau method:148.84?1.05 cm (142.59-153.56 cm,llF) and 162.1 cm(1M)and a growth velocity (GV) of 5.76 2 0.49 cmlyr (4.0-10.2 cm/yr).Puberty was temporarily blocked with a long-acting GnGH analog (DTrp6-LHRH,Decapeptyl).60 ug/Kg/month.im). Hormonal data were obtained before and after 6 months (m) of therapy and auxological data after 6m.12m and 18m.The 125 I-hGH was incubated with 150 ul of serum. bound and free GH were separated by gel filtration, and the ratio of bound (bound+free) labelled GH was considered as GHBP. Pretreatment GHBP (25.94+1.68%) was not different from the control group (27.0+0.8%)and did not change after 6mo of therapy (26.722.3W.There was a significant decrease in peack GH levels the ornithine stimulation test (p<0.002) and during sleep (p<0.002) after 6m of therapy. The bone age maturation was already slower by 6mo (p<0.002) and more significantly by 18mo (p<0.001). The GV diminished by 12m(p< 0.05) and 1Bm (p<0.005).The improvement in final height prediction was 2.233.91(p<0.05)by 6m and 3.283.78 cm(p<0.002) by 18m of therapy.A follow-up to final height is necessary to confirm the possible beneficial effects of this therapy. W C should be screened in all children over By-old born from affected cases.since MTC may present as an inherited tumor.In our experience, a combined test injecting pentagastrin (Pg) 0.5 UI/Kg and calcium (Ca++) Zmg/Kg.with serum calcitonin (CT) measurements (0.2.5 and 10 min), has been proved to be a reliable screening test for occult W C in children. In this study 12 prepubertal and pubertal individuals (M:4. F:8) were tested. they belonged to two sibships with an affected pattern. Five of these cases showed CT hyperresponsiveness (>350 pg/ml) during Pg+Ca++ tests.al1 were females. At least two abnormal tests were detected in each case in order to establish the biochemical diagnosis of W C and/or "C" cell hyperplasia.that preceeds the familial form of WC.Three of the affected cases had no palpable thyroid nodules whereas it was palpable in two. Total thyroidectomy associated with preventive lymphnode resection was performed in all affected cases.Pathologyca1 findings confirmed the presence of MTC in all. After surgery. basal CT levels dropped to normal values and the exagerated response to Pg+Ca++ disappeared in the cases without palpable nodules. In those cases with palpable thyroid nodules, basal CT remained high despite a significant reduction after surgery. augmented CT responsiveness was also present in these latter cases. It is concluded that 1) In prepubertal and pubertal cases early detection of W C usually leads to definitive cure after surgery. 2) cases with palpable thyroid nodules(1ate detection)due to W C frequently do not achieve cure.as revealed by persistently high serum levels of the tumor marker CT.
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THERAPY OF IDIOPATHIC SHORT STATURE WITH LONG-ACTING GnRH AN-: EFFECTS ON GROWTH HORMONE (GH). GROWTH HORMONE-BINDING PROTEIN
